Literature DB >> 25855749

CD8+ T Cells Can Mediate Short-Term Protection against Heterotypic Dengue Virus Reinfection in Mice.

Raphaël M Zellweger1, William W Tang1, William E Eddy1, Kevin King1, Marisa C Sanchez1, Sujan Shresta2.   

Abstract

UNLABELLED: Dengue virus (DENV) is a major public health threat worldwide. Infection with one of the four serotypes of DENV results in a transient period of protection against reinfection with all serotypes (cross-protection), followed by lifelong immunity to the infecting serotype. While a protective role for neutralizing antibody responses is well established, the contribution of T cells to reinfection is less clear, especially during heterotypic reinfection. This study investigates the role of T cells during homotypic and heterotypic DENV reinfection. Mice were sequentially infected with homotypic or heterotypic DENV serotypes, and T cell subsets were depleted before the second infection to assess the role of DENV-primed T cells during reinfection. Mice primed nonlethally with DENV were protected against reinfection with either a homotypic or heterotypic serotype 2 weeks later. Homotypic priming induced a robust neutralizing antibody response, whereas heterotypic priming elicited binding, but nonneutralizing antibodies. CD8(+) T cells were required for protection against heterotypic, but not homotypic, reinfection. These results suggest that T cells can contribute crucially to protection against heterotypic reinfection in situations where humoral responses alone may not be protective. Our findings have important implications for vaccine design, as they suggest that inducing both humoral and cellular responses during vaccination may maximize protective efficacy across all DENV serotypes. IMPORTANCE: Dengue virus is present in more than 120 countries in tropical and subtropical regions. Infection with dengue virus can be asymptomatic, but it can also progress into the potentially lethal severe dengue disease. There are four closely related dengue virus serotypes. Infection with one serotype results in a transient period of resistance against all serotypes (cross-protection), followed by lifelong resistance to the infecting serotype, but not the other ones. The duration and mechanisms of the transient cross-protection period remain elusive. This study investigates the contribution of cellular immunity to cross-protection using mouse models of DENV infection. Our results demonstrate that cellular immunity is crucial to mediate cross-protection against reinfection with a different serotype, but not for protection against reinfection with the same serotype. A better understanding of the mediators responsible for the cross-protection period is important for vaccine design, as an ideal vaccine against dengue virus should efficiently protect against all serotypes.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25855749      PMCID: PMC4474296          DOI: 10.1128/JVI.00036-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  58 in total

1.  Efficacy of a tetravalent dengue vaccine in children in Latin America.

Authors:  Luis Villar; Gustavo Horacio Dayan; José Luis Arredondo-García; Doris Maribel Rivera; Rivaldo Cunha; Carmen Deseda; Humberto Reynales; Maria Selma Costa; Javier Osvaldo Morales-Ramírez; Gabriel Carrasquilla; Luis Carlos Rey; Reynaldo Dietze; Kleber Luz; Enrique Rivas; Maria Consuelo Miranda Montoya; Margarita Cortés Supelano; Betzana Zambrano; Edith Langevin; Mark Boaz; Nadia Tornieporth; Melanie Saville; Fernando Noriega
Journal:  N Engl J Med       Date:  2014-11-03       Impact factor: 91.245

2.  Detection of intracellular cytokines by flow cytometry.

Authors:  Barbara Foster; Calman Prussin; Fei Liu; Jason K Whitmire; J Lindsay Whitton
Journal:  Curr Protoc Immunol       Date:  2007-08

3.  Comprehensive analysis of dengue virus-specific responses supports an HLA-linked protective role for CD8+ T cells.

Authors:  Daniela Weiskopf; Michael A Angelo; Elzinandes L de Azeredo; John Sidney; Jason A Greenbaum; Anira N Fernando; Anne Broadwater; Ravi V Kolla; Aruna D De Silva; Aravinda M de Silva; Kimberly A Mattia; Benjamin J Doranz; Howard M Grey; Sujan Shresta; Bjoern Peters; Alessandro Sette
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-11       Impact factor: 11.205

4.  Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial.

Authors:  Arunee Sabchareon; Derek Wallace; Chukiat Sirivichayakul; Kriengsak Limkittikul; Pornthep Chanthavanich; Saravudh Suvannadabba; Vithaya Jiwariyavej; Wut Dulyachai; Krisana Pengsaa; T Anh Wartel; Annick Moureau; Melanie Saville; Alain Bouckenooghe; Simonetta Viviani; Nadia G Tornieporth; Jean Lang
Journal:  Lancet       Date:  2012-09-11       Impact factor: 79.321

5.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

Review 6.  Neurological complications of dengue virus infection.

Authors:  Francisco Javier Carod-Artal; Ole Wichmann; Jeremy Farrar; Joaquim Gascón
Journal:  Lancet Neurol       Date:  2013-09       Impact factor: 44.182

Review 7.  The human antibody response to dengue virus infection.

Authors:  Wahala M P B Wahala; Aravinda M de Silva
Journal:  Viruses       Date:  2011-11-25       Impact factor: 5.048

Review 8.  Mouse models to study dengue virus immunology and pathogenesis.

Authors:  Raphaël M Zellweger; Sujan Shresta
Journal:  Front Immunol       Date:  2014-04-10       Impact factor: 7.561

9.  Role of humoral versus cellular responses induced by a protective dengue vaccine candidate.

Authors:  Raphaël M Zellweger; Robyn Miller; William E Eddy; Laura J White; Robert E Johnston; Sujan Shresta
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

10.  Neutralizing antibodies after infection with dengue 1 virus.

Authors:  Maria G Guzman; Mayling Alvarez; Rosmari Rodriguez-Roche; Lidice Bernardo; Tibaire Montes; Susana Vazquez; Luis Morier; Angel Alvarez; Ernest A Gould; Gustavo Kouri; Scott B Halstead
Journal:  Emerg Infect Dis       Date:  2007-02       Impact factor: 6.883

View more
  47 in total

1.  Mapping and Role of the CD8+ T Cell Response During Primary Zika Virus Infection in Mice.

Authors:  Annie Elong Ngono; Edward A Vizcarra; William W Tang; Nicholas Sheets; Yunichel Joo; Kenneth Kim; Matthew J Gorman; Michael S Diamond; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2017-01-11       Impact factor: 21.023

2.  Immunodominant Dengue Virus-Specific CD8+ T Cell Responses Are Associated with a Memory PD-1+ Phenotype.

Authors:  Ruklanthi de Alwis; Derek J Bangs; Michael A Angelo; Cristhiam Cerpas; Anira Fernando; John Sidney; Bjoern Peters; Lionel Gresh; Angel Balmaseda; Aruna D de Silva; Eva Harris; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2016-04-14       Impact factor: 5.103

3.  Host response: Cross-fit T cells battle Zika virus.

Authors:  Matthew Collins; Aravinda de Silva
Journal:  Nat Microbiol       Date:  2017-05-25       Impact factor: 17.745

Review 4.  Antigenic cross-reactivity between Zika and dengue viruses: is it time to develop a universal vaccine?

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  Curr Opin Immunol       Date:  2019-03-15       Impact factor: 7.486

5.  Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.

Authors:  Yuan Tian; Mariana Babor; Jerome Lane; Grégory Seumois; Shu Liang; N D Suraj Goonawardhana; Aruna D De Silva; Elizabeth J Phillips; Simon A Mallal; Ricardo da Silva Antunes; Alba Grifoni; Pandurangan Vijayanand; Daniela Weiskopf; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

Review 6.  T Cell Immunity to Zika and Dengue Viral Infections.

Authors:  Jinsheng Wen; Sujan Shresta
Journal:  J Interferon Cytokine Res       Date:  2017-11       Impact factor: 2.607

7.  Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Authors:  Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

Review 8.  Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine.

Authors:  Huabin Liang; Min Lee; Xia Jin
Journal:  Cell Mol Immunol       Date:  2015-10-05       Impact factor: 11.530

9.  A Mouse Model of Zika Virus Pathogenesis.

Authors:  Helen M Lazear; Jennifer Govero; Amber M Smith; Derek J Platt; Estefania Fernandez; Jonathan J Miner; Michael S Diamond
Journal:  Cell Host Microbe       Date:  2016-04-05       Impact factor: 21.023

10.  Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells.

Authors:  Jinsheng Wen; William Weihao Tang; Nicholas Sheets; Julia Ellison; Alessandro Sette; Kenneth Kim; Sujan Shresta
Journal:  Nat Microbiol       Date:  2017-03-13       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.